Aerpio Reports Q4 and Full Year 2019 Financial Results

Aerpio Pharmaceuticals (NASDAQ:ARPO) reported financial results for the fourth quarter and full year ended December 31, 2019.

As quoted in the press release:

“We ended the year with a strong cash position, $38.5 million, and with promising results in our Phase 1b glaucoma clinical trial,” said Joseph Gardner, Ph.D., President and Founder of Aerpio. “A mean reduction in intraocular pressure of 1.58 mmHg on top of standard of care prostaglandins, was observed in cohort five which included patients with ocular hypertension (OH) and primary open angle glaucoma patients (OAG). The mean intraocular pressure (IOP) reduction was statistically significant after only 7 days of dosing and the tolerability was favorable with minimal hyperemia. These results set us up to run a Phase 2 trial starting in the third quarter of this year. We have reviewed the study results with glaucoma experts who support moving forward with further development. Once initiated, we expect topline results from this trial to read out in the first quarter of 2021.”

Click here to read the full press release.